Table 1.
Demographics and baseline disease characteristics
| Characteristic | Placebo Q2W n = 26 |
CZP 400 mg Q2W n = 53 |
CZP 200 mg Q2W n = 48 |
|---|---|---|---|
| Demographics | |||
| Age, years, mean ± SD | 47.9 ± 11.4 | 52.4 ± 11.6 | 48.4 ± 13.5 |
| Male, n (%) | 21 (80.8) | 42 (79.2) | 36 (75.0) |
| Weight, kg, mean ± SD | 75.1 ± 15.8 | 71.6 ± 14.3 | 72.6 ± 14.3 |
| Height, cm, mean ± SD | 165.7 ± 7.1 | 165.6 ± 7.5 | 167.5 ± 7.5 |
| BMI, kg/m2, mean ± SD | 27.3 ± 5.1 | 26.0 ± 4.3 | 26.0 ± 5.5 |
| Baseline disease characteristics | |||
| Duration of disease, years, mean ± SD | 12.7 ± 8.6 | 13.2 ± 9.3 | 12.7 ± 10.1 |
| Concurrent PsA, n (%) | 5 (19.2) | 10 (18.9) | 6 (12.5) |
| PASI, mean ± SD | 24.5 ± 10.4 | 26.5 ± 11.0 | 24.5 ± 12.6 |
| DLQI, mean ± SD | 10.5 ± 7.2 | 9.2 ± 7.4 | 10.5 ± 6.6 |
| INRS, mean ± SD | 6.1 ± 2.5 | 5.7 ± 2.6 | 5.6 ± 2.4 |
| BSA affected, %, mean ± SD | 38.3 ± 17.2 | 39.7 ± 21.4 | 38.7 ± 21.9 |
| PGA score, n (%) | |||
| 3: moderate | 17 (65.4) | 31 (58.5) | 31 (64.6) |
| 4: severe | 9 (34.6) | 22 (41.5) | 17 (35.4) |
| Any systematic PSO treatment, n (%) | 20 (76.9) | 37 (69.8) | 39 (81.3) |
| Prior biologic use, n (%) | |||
| One therapy | 8 (30.8) | 16 (30.2) | 14 (29.2) |
| Two therapies | 0 (0) | 3 (5.7) | 0 (0) |
| Anti-TNF | 1 (3.8) | 3 (5.7) | 3 (6.3) |
Full analysis set. BMI body mass index, BSA body surface area, CZP certolizumab pegol, DLQI Dermatology Life Quality Index, INRS Itch Numeric Rating Scale, PASI Psoriasis Area and Severity Index, PGA Physician’s Global Assessment, PsA psoriatic arthritis, PSO plaque psoriasis, Q2W every 2 weeks, SD standard deviation, TNF tumour necrosis factor